Mendus announces positive data from the ALISON trial in ovarian cancer presented at the AACR Annual Meeting 2023
VIDIDENCEL INDUCES DURABLE VACCINE-INDUCED T-CELL RESPONSES IN THE MAJORITY OF PATIENTS
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced the presentation of new clinical data from the Phase 1 ALISON ovarian cancer trial at the American Association for Cancer Research (AACR) Annual Meeting 2023. The data were presented as part of the Immunomodulatory Agents and Interventions Session held April 18, 2023 9:00 AM - 12:30 PM ET by researchers from the Department of Obstetrics and Gynaecology, University Medical Center Groningen, The Netherlands, where the ALISON trial is carried out. The poster presented at AACR is now available on Mendus website and can be accessed via the following link:
The data presented at AACR demonstrate that vididencel treatment is safe, well-tolerated and induces durable T-cell responses to tumor associated antigens in ovarian cancer patients. At the time of the data cut (March 17, 2023) 11 patients were enrolled in the trial, of which 7 had completed vididencel vaccination and 4 were still on treatment. In total 4 patients had recurred, of which one died. Immune responses were evaluated in 5 patients and 4 patients demonstrated durable vaccine-induced T cell responses (VIR) against at least one tumor-associated antigen. The 1 patient not showing a VIR already had high base line responses against all four antigens measured. Thus far, vididencel showed only mild to moderate adverse events after intradermal administration. In all patients, an injection site reaction was observed, which resolved over a few days, confirming the intradermal immune response induced. Combined, the data presented at AACR show that vididencel is capable of inducing durable T cell responses against tumor associated antigens previously shown to be relevant in ovarian cancer and continues to be safe and well tolerated. Based on the initial positive data, the ALISON study will continue to enroll new patients.
The Phase 1 ALISON trial (NCT04739527) is a single-center, open-label trial evaluating safety and efficacy of vididencel (DCP-001) in High-Grade Serous Ovarian Cancer (HGSOC) patients. Treatment of HGSOC after debulking and chemotherapy remains challenging, due to a high risk of chemotherapy resistance and disease relapse. The ALISON trial evaluates the use of vididencel as a maintenance immunotherapy, aimed to prolong disease-free survival following primary treatment. The primary endpoint of the trial is the number of patients with vididencel induced antigen-specific T cells responses in peripheral blood after treatment. Key secondary endpoints include safety and tolerability after repeated vididencel dosing, as well as recurrence free survival (RFS) and overall survival (OS) during a 2-year follow-up period. Patient enrolment and further analysis of vididencel induced immune responses will continue in 2023.
ABOUT THE AACR ANNUAL MEETING
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting
Chief Executive Officer
E-mail:
INVESTOR RELATIONS
Corey Davis
LifeSci Advisors, LLC
Telephone: 7
E-mail:
MEDIA RELATIONS
Mario Brkulj
Valency Communications
Telephone: 51
E-mail:
Attachment
